Quince Therapeutics president to exit Sept 2026

Quince Therapeutics, Inc. (QNCX) reported a leadership change in which President Charles Ryan and the company determined that his last day of employment will be September 8, 2026.

Rhea-AI Filing Summary

Quince Therapeutics, Inc. (QNCX) reported a leadership change in which President Charles Ryan and the company determined that his last day of employment will be September 8, 2026. In connection with the end of his service as President, he will be eligible for severance benefits under his existing Executive Change in Control and Severance Agreement dated September 1, 2023, as previously described in Quince Therapeutics’ definitive proxy statement on Schedule 14A filed with the SEC on August 25, 2026.

Positive

• None.

Negative

• President departure: The company disclosed that its President, Charles Ryan, will leave effective September 8, 2026, representing a significant leadership change.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Key Figures

Last day of employment: September 8, 2026 Executive Change in Control and Severance Agreement date: September 1, 2023 Schedule 14A filing date: August 25, 2026

3 metrics

Last day of employment September 8, 2026 Effective date for Charles Ryan’s departure as President

Executive Change in Control and Severance Agreement date September 1, 2023 Date of the agreement governing Charles Ryan’s severance eligibility

Schedule 14A filing date August 25, 2026 Date of the definitive proxy statement describing potential payments upon termination or change of control

Key Terms

Executive Change in Control and Severance Agreement, definitive proxy statement, Schedule 14A, Item 5.02

4 terms

Executive Change in Control and Severance Agreement financial

"under the terms of his Executive Change in Control and Severance Agreement, dated September 1, 2023"

definitive proxy statement regulatory

"in the Company’s definitive proxy statement on Schedule 14A, filed"

A Definitive Proxy Statement is a detailed document that a company sends to its shareholders before a big meeting, like voting on important decisions. It explains what's being voted on and gives important information so shareholders can make informed choices. It matters because it helps shareholders understand and participate in key company decisions.

Schedule 14A regulatory

"in the Company’s definitive proxy statement on Schedule 14A, filed"

Schedule 14A is a document that companies file with regulators to share important information with shareholders before a big vote, like approving a merger or election of directors. It matters because it helps investors understand what’s happening so they can make informed decisions about the company’s future.

Item 5.02 regulatory

"Item 5.02. Departure of Directors or Certain Officers; Election of Directors"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What leadership change did Quince Therapeutics (QNCX) announce on August 23, 2026?

Quince Therapeutics announced that its President, Charles Ryan, and the company determined that his last day of employment will be September 8, 2026, constituting a leadership transition at the president level.

When is Charles Ryan’s last day as President of Quince Therapeutics (QNCX)?

Charles Ryan’s last day of employment as President of Quince Therapeutics is September 8, 2026, as agreed between him and the company.

Is Charles Ryan receiving severance benefits from Quince Therapeutics (QNCX)?

Yes. In connection with the conclusion of his service as President, Charles Ryan will be eligible for certain severance benefits under his Executive Change in Control and Severance Agreement dated September 1, 2023.

Where are the details of Charles Ryan’s severance arrangement at Quince Therapeutics (QNCX) described?

The company states that details of Charles Ryan’s potential severance payments are described under “Executive Compensation—Potential Payments Upon Termination or Change of Control” in its definitive proxy statement on Schedule 14A filed with the SEC on August 25, 2026.

What SEC form did Quince Therapeutics (QNCX) use to report the President’s departure?

Quince Therapeutics reported the President’s departure on a Form 8-K under the item covering departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/27/2026 - 04:31 PM EDT Accepted by SEC EDGAR 08/27/2026 - 04:30 PM EDT Learn about SEC filing dates

false 0001662774 0001662774 2026-08-23 2026-08-23

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 23, 2026

QUINCE THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-38890		90-1024039
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

611 Gateway Boulevard, Suite 273
South San Francisco, California		94080
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (415) 910-5717

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13d-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001 per share		QNCX		Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On August 23, 2026, Quince Therapeutics, Inc. (the “Company”) and Charles Ryan, the Company’s President, determined that Mr. Ryan’s last day of employment will be September 8, 2026. In connection with the conclusion of his service as the Company’s President, Mr. Ryan will be eligible for certain severance benefits under the terms of his Executive Change in Control and Severance Agreement, dated September 1, 2023, by and between Mr. Ryan and the Company, as described under “Executive Compensation—Potential Payments Upon Termination or Change of Control” in the Company’s definitive proxy statement on Schedule 14A, filed with the Securities and Exchange Commission on August 25, 2026.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

				Quince Therapeutics, Inc.
				By:		/s/ Dirk Thye
Date: August 27, 2026				Name:		Dirk Thye
				Title:		Chief Executive Officer

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA 3.1 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE 17.6 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE 11.0 KB